Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E31.27 EPS (ttm)19.90 Insider Own1.10% Shs Outstand109.80M Perf Week0.40%
Market Cap62.37B Forward P/E19.65 EPS next Y31.68 Insider Trans-42.51% Shs Float87.32M Perf Month3.01%
Income2.28B PEG3.71 EPS next Q6.10 Inst Own76.80% Short Float2.83% Perf Quarter24.80%
Sales7.98B P/S7.82 EPS this Y-10.80% Inst Trans2.20% Short Ratio1.78 Perf Half Y66.72%
Book/sh110.50 P/B5.63 EPS next Y17.68% ROA15.80% Target Price616.96 Perf Year95.50%
Cash/sh39.95 P/C15.58 EPS next 5Y8.44% ROE21.00% 52W Range271.37 - 646.33 Perf YTD65.77%
Dividend- P/FCF36.57 EPS past 5Y44.00% ROI16.10% 52W High-3.69% Beta0.56
Dividend %- Quick Ratio3.70 Sales past 5Y22.80% Gross Margin89.70% 52W Low129.37% ATR23.27
Employees8100 Current Ratio4.20 Sales Q/Q33.20% Oper. Margin30.50% RSI (14)55.47 Volatility2.88% 3.57%
OptionableYes Debt/Eq0.06 EPS Q/Q35.90% Profit Margin28.60% Rel Volume0.57 Prev Close609.17
ShortableYes LT Debt/Eq0.06 EarningsMay 05 BMO Payout0.00% Avg Volume1.39M Price622.45
Recom2.10 SMA202.34% SMA507.04% SMA20044.20% Volume790,998 Change2.18%
May-26-20Upgrade Wells Fargo Equal Weight → Overweight $559 → $734
Apr-28-20Downgrade Citigroup Buy → Neutral $540 → $575
Apr-17-20Upgrade The Benchmark Company Hold → Buy $655
Apr-08-20Initiated The Benchmark Company Hold
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $530
Feb-26-20Upgrade Canaccord Genuity Hold → Buy $550
Feb-26-20Downgrade Robert W. Baird Outperform → Neutral $410
Feb-25-20Upgrade Jefferies Hold → Buy $355 → $492
Feb-11-20Upgrade Argus Hold → Buy $430
Dec-24-19Initiated Raymond James Mkt Perform
Dec-16-19Downgrade Evercore ISI Outperform → In-line
Dec-13-19Upgrade Credit Suisse Neutral → Outperform $400
Nov-12-19Initiated SunTrust Hold $360
Nov-07-19Upgrade Citigroup Neutral → Buy $340 → $420
Oct-17-19Resumed BofA/Merrill Neutral $325
Sep-23-19Upgrade Guggenheim Neutral → Buy $355 → $403
Aug-07-19Upgrade Robert W. Baird Neutral → Outperform $410
Jun-18-19Downgrade Argus Buy → Hold
May-23-19Resumed Citigroup Neutral
Jul-05-20 10:53PM  
06:27AM  
Jul-03-20 12:36PM  
08:22AM  
06:48AM  
06:01AM  
Jul-02-20 10:47PM  
10:15PM  
04:59PM  
04:44PM  
04:37PM  
04:29PM  
12:54PM  
11:00AM  
Jul-01-20 11:40AM  
11:28AM  
Jun-30-20 03:13PM  
01:28PM  
12:23PM  
Jun-29-20 10:48AM  
09:12AM  
Jun-26-20 09:30PM  
09:41AM  
Jun-25-20 03:26PM  
01:44PM  
Jun-24-20 03:22PM  
02:00PM  
12:57PM  
12:23PM  
08:07AM  
Jun-23-20 05:45PM  
11:40AM  
Jun-22-20 11:18AM  
09:42AM  
09:34AM  
08:12AM  
07:32AM  
07:00AM  
Jun-19-20 05:13PM  
01:51PM  
01:44PM  
07:40AM  
07:30AM  
Jun-17-20 09:53AM  
06:38AM  
Jun-16-20 05:45PM  
06:51AM  
Jun-15-20 03:50PM  
03:18PM  
02:49PM  
11:40AM  
07:36AM  
Jun-13-20 08:21AM  
Jun-12-20 09:15AM  
07:30AM  
Jun-11-20 10:36PM  
04:37PM  
04:26PM  
03:28PM  
03:05PM  
02:42PM  
02:02PM  
10:53AM  
10:46AM  
09:59AM  
09:29AM  
08:54AM  
08:14AM  
07:26AM  
07:01AM  
07:00AM  
07:00AM  
01:12AM  
12:59AM  
Jun-10-20 06:59PM  
05:45PM  
09:00AM  
05:22AM  
Jun-09-20 08:20AM  
06:41AM  
02:56AM  
Jun-08-20 10:00AM  
09:00AM  
Jun-06-20 12:03PM  
Jun-05-20 02:00PM  
01:22PM  
07:00AM  
Jun-04-20 01:41PM  
11:31AM  
Jun-03-20 05:02PM  
03:13PM  
09:56AM  
06:25AM  
06:13AM  
Jun-02-20 01:49PM  
11:09AM  
11:00AM  
10:53AM  
09:15AM  
08:00AM  
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services for the development of new treatments combating the coronavirus. It also has a collaboration with Zai Lab Limited and Intellia Therapeutics, Inc. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BROWN MICHAEL SDirectorJul 01Option Exercise413.333,6131,493,3614,256Jul 02 04:02 PM
BROWN MICHAEL SDirectorJul 01Sale607.623,6132,195,342643Jul 02 04:02 PM
RYAN ARTHUR FDirectorJul 01Sale609.7010060,97028,643Jul 02 04:01 PM
SING GEORGE LDirectorJun 29Sale608.913,0001,826,7211,400Jun 29 04:08 PM
Landry Robert EEVP Finance CFOJun 29Sale612.57400245,02923,973Jun 30 04:02 PM
Landry Robert EEVP Finance CFOJun 23Sale631.27512323,21224,373Jun 24 04:03 PM
Landry Robert EEVP Finance CFOJun 22Option Exercise555.678,9004,945,46333,273Jun 24 04:03 PM
Bassler Bonnie LDirectorJun 19Option Exercise391.922,5591,002,9233,202Jun 22 04:18 PM
Bassler Bonnie LDirectorJun 19Sale630.022,5591,612,211643Jun 22 04:18 PM
Fenimore Christopher R.VP ControllerJun 16Sale590.893,5562,101,21515,277Jun 17 04:02 PM
Fenimore Christopher R.VP ControllerJun 15Option Exercise47.079,406442,74220,323Jun 17 04:02 PM
Zoghbi Huda YDirectorJun 11Option Exercise391.921,706668,6162,349Jun 12 04:03 PM
Zoghbi Huda YDirectorJun 11Sale625.001,7061,066,250643Jun 12 04:03 PM
Landry Robert EEVP Finance CFOJun 11Sale612.08988604,73124,373Jun 12 04:01 PM
Landry Robert EEVP Finance CFOJun 10Option Exercise272.703,500954,45027,873Jun 12 04:01 PM
Zoghbi Huda YDirectorJun 10Option Exercise391.921,706668,6162,349Jun 12 04:03 PM
Zoghbi Huda YDirectorJun 10Sale610.241,7061,041,068643Jun 12 04:03 PM
Landry Robert EEVP Finance CFOJun 09Sale608.014,2712,596,79224,373Jun 10 04:04 PM
GOLDSTEIN JOSEPH LDirectorJun 08Option Exercise413.3310,8384,479,67117,481Jun 09 04:05 PM
Landry Robert EEVP Finance CFOJun 08Option Exercise272.7015,5004,226,85029,860Jun 10 04:04 PM
GOLDSTEIN JOSEPH LDirectorJun 08Sale592.9510,8386,426,3626,643Jun 09 04:05 PM
Bassler Bonnie LDirectorJun 05Option Exercise391.922,5591,002,9233,202Jun 05 04:15 PM
Bassler Bonnie LDirectorJun 05Sale600.002,5591,535,400643Jun 05 04:15 PM
RYAN ARTHUR FDirectorJun 01Sale603.2310060,32328,743Jun 02 04:04 PM
SING GEORGE LDirectorMay 29Sale596.511,000596,5102,400Jun 01 04:08 PM
GOLDSTEIN JOSEPH LDirectorMay 28Sale578.941,000578,9406,643Jun 01 04:02 PM
SING GEORGE LDirectorMay 28Sale579.001,000579,0002,900Jun 01 04:08 PM
VAGELOS P ROYChairman of the BoardMay 21Sale577.49783452,178307,749May 22 06:21 PM
VAGELOS P ROYChairman of the BoardMay 21Sale564.37148,81183,984,786308,532May 22 06:21 PM
VAGELOS P ROYChairman of the BoardMay 20Option Exercise30.63312,5009,571,875497,063May 22 06:21 PM
LAROSA JOSEPH JEVP General Counsel and SecretMay 15Sale572.008,3804,793,36014,438May 15 04:03 PM
LAROSA JOSEPH JEVP General Counsel and SecretMay 14Option Exercise59.2018,3111,084,01132,749May 15 04:03 PM
SING GEORGE LDirectorMay 13Option Exercise33.425,000167,100120,415May 13 09:00 PM
SING GEORGE LDirectorMay 13Sale580.005,0002,900,000115,415May 13 09:00 PM
SCHLEIFER LEONARD SPresident & CEOMay 12Sale569.22150,92285,908,042474,499May 13 09:01 PM
SCHLEIFER LEONARD SPresident & CEOMay 11Option Exercise30.63312,5009,571,875722,368May 13 09:01 PM
SING GEORGE LDirectorMay 11Sale575.00850488,7502,150May 13 09:00 PM
STAHL NEILEVP Research and DevelopmentMay 11Sale569.525,3053,021,28911,380May 11 04:39 PM
STAHL NEILEVP Research and DevelopmentMay 08Option Exercise52.0312,500650,37523,880May 11 04:39 PM
Zoghbi Huda YDirectorMay 07Option Exercise391.925,1182,005,8475,761May 08 04:03 PM
Zoghbi Huda YDirectorMay 07Sale566.525,1182,899,461643May 08 04:03 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 07Sale564.3239,58322,337,30628,251May 08 04:04 PM
BROWN MICHAEL SDirectorMay 07Sale562.001,8091,016,658643May 07 04:14 PM
BROWN MICHAEL SDirectorMay 06Option Exercise371.985,4702,034,7395,863May 07 04:14 PM
Tessier-Lavigne MarcDirectorMay 06Option Exercise177.8215,0002,667,30016,830May 08 04:03 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 06Option Exercise52.0385,5794,452,67596,051May 08 04:04 PM
RYAN ARTHUR FDirectorMay 06Option Exercise373.6750,12418,729,67078,967May 07 06:22 PM
GOLDSTEIN JOSEPH LDirectorMay 06Sale560.002,0001,120,0007,643May 06 04:19 PM
RYAN ARTHUR FDirectorMay 06Sale550.8850,12427,612,50928,843May 07 06:22 PM
Tessier-Lavigne MarcDirectorMay 06Sale563.9715,0008,459,4961,830May 08 04:03 PM
RYAN ARTHUR FDirectorMay 01Sale520.3710052,03728,843May 04 04:02 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 20Sale570.301,7781,013,98514,438Apr 20 07:27 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 20Sale565.483,5221,991,61116,216Apr 20 07:26 PM
Landry Robert EEVP Finance CFOApr 20Sale566.943,2501,842,53924,373Apr 20 07:29 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 17Option Exercise59.2011,622688,02222,458Apr 20 07:26 PM
Landry Robert EEVP Finance CFOApr 17Option Exercise272.7012,5003,408,75036,873Apr 20 07:29 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 17Sale557.382,2671,263,58614,438Apr 20 07:26 PM
Landry Robert EEVP Finance CFOApr 17Sale557.68991552,66124,373Apr 20 07:29 PM
Landry Robert EEVP Finance CFOApr 16Option Exercise272.704,0001,090,80028,373Apr 20 07:29 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 16Option Exercise59.205,000296,00019,438Apr 20 07:26 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 15Sale518.212,2621,172,18714,438Apr 16 04:04 PM
Landry Robert EEVP Finance CFOApr 15Sale518.49853442,27624,373Apr 16 04:03 PM
Landry Robert EEVP Finance CFOApr 14Option Exercise272.703,500954,45027,873Apr 16 04:03 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 14Option Exercise59.205,000296,00019,438Apr 16 04:04 PM
STAHL NEILEVP Research and DevelopmentApr 14Sale521.075,4972,864,30711,380Apr 15 04:17 PM
STAHL NEILEVP Research and DevelopmentApr 13Option Exercise52.0313,079680,50024,459Apr 15 04:17 PM
Landry Robert EEVP Finance CFOApr 13Sale509.79828422,10824,373Apr 13 07:23 PM
Landry Robert EEVP Finance CFOApr 09Option Exercise272.703,500954,45027,873Apr 13 07:23 PM
Landry Robert EEVP Finance CFOApr 07Sale497.52696346,27124,373Apr 08 04:02 PM
Landry Robert EEVP Finance CFOApr 06Option Exercise272.703,000818,10027,373Apr 08 04:02 PM
Landry Robert EEVP Finance CFOApr 03Sale494.28683337,59224,373Apr 03 04:50 PM
Landry Robert EEVP Finance CFOApr 02Option Exercise272.703,000818,10028,726Apr 03 04:49 PM
Landry Robert EEVP Finance CFOApr 02Sale495.8810552,06825,056Apr 03 04:50 PM
Landry Robert EEVP Finance CFOApr 02Sale489.321,248610,67225,161Apr 03 04:49 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 02Sale489.986,7973,330,40614,438Apr 03 04:08 PM
Fenimore Christopher R.VP ControllerApr 01Option Exercise30.631,20036,75614,297Apr 03 04:05 PM
Landry Robert EEVP Finance CFOApr 01Option Exercise272.706,0001,636,20026,937Apr 03 04:49 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 01Option Exercise59.2015,000888,00023,924Apr 03 04:08 PM
Landry Robert EEVP Finance CFOApr 01Sale488.02600292,81124,373Apr 03 04:49 PM
Fenimore Christopher R.VP ControllerApr 01Sale488.411,200586,09613,097Apr 03 04:05 PM
RYAN ARTHUR FDirectorApr 01Sale483.8510048,38528,943Apr 01 06:49 PM
RYAN ARTHUR FDirectorMar 30Sale466.6910046,66929,043Apr 01 06:49 PM
YANCOPOULOS GEORGEPresident and Chief ScientificMar 10Sale470.47117,81555,428,041517,799Mar 11 04:05 PM
YANCOPOULOS GEORGEPresident and Chief ScientificMar 09Option Exercise30.63246,7367,557,524713,990Mar 11 04:05 PM
GOLDSTEIN JOSEPH LDirectorMar 09Option Exercise33.422,00066,84011,643Mar 10 04:05 PM
GOLDSTEIN JOSEPH LDirectorMar 09Sale475.842,000951,6849,643Mar 10 04:05 PM
STAHL NEILEVP Research and DevelopmentFeb 27Sale452.2610,3494,680,46011,380Feb 28 04:40 PM
SING GEORGE LDirectorFeb 26Option Exercise33.422,50083,550117,915Feb 28 04:30 PM
STAHL NEILEVP Research and DevelopmentFeb 26Option Exercise52.0325,0001,300,75036,380Feb 28 04:40 PM
Landry Robert EEVP Finance CFOFeb 26Sale456.2120091,24224,973Feb 26 06:14 PM
Van Plew Daniel PEVP & General Mgr Industrial OFeb 26Sale457.2315,6427,152,01628,251Feb 27 04:12 PM
SING GEORGE LDirectorFeb 26Sale460.002,5001,150,000115,415Feb 28 04:30 PM
SING GEORGE LDirectorFeb 26Sale452.832,4001,086,8002,400Feb 28 04:30 PM
Van Plew Daniel PEVP & General Mgr Industrial OFeb 25Option Exercise30.6332,7351,002,67360,986Feb 27 04:12 PM
Landry Robert EEVP Finance CFOFeb 25Option Exercise272.701,000272,70026,187Feb 26 06:14 PM
Landry Robert EEVP Finance CFOFeb 25Sale449.0121496,08825,173Feb 26 06:14 PM
Landry Robert EEVP Finance CFOFeb 24Option Exercise272.701,000272,70025,973Feb 26 06:14 PM
BROWN MICHAEL SDirectorFeb 24Option Exercise273.672,000547,3402,643Feb 25 04:03 PM
BROWN MICHAEL SDirectorFeb 24Sale419.002,000838,001643Feb 25 04:03 PM
YANCOPOULOS GEORGEPresident and Chief ScientificFeb 24Sale420.17118,12349,631,741517,799Feb 25 04:05 PM